Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
Impact in
- Oncology 907
- Immunology 717
Classified as
Countries where authors are citing Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
This map shows the geographic impact of Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens more than expected).
Fields of papers citing Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
This network shows the impact of Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens.
About Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
This paper, published in 2008, received 1.1k indexed citations . Written by Mark E. Dudley, James Chih‐Hsin Yang, Richard Mark Sherry, Marybeth S. Hughes, Richard Eldon Royal, Udai S. Kammula, Paul F. Robbins, Deborah E. Citrin, Susan F. Leitman and John R. Wunderlich covering the research area of Oncology. It is primarily cited by scholars working on Oncology (907 citations), Immunology (717 citations), Genetics (237 citations), Molecular Biology (210 citations) and Biomedical Engineering (57 citations). Published in Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/10.1200/jco.2008.16.5449.